INFORMATION INTENDED FOR GLOBAL HEALTHCARE PROFESSIONALS

Healthcare Professionals

GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics through our proven drug discovery and development processes, our intellectual property portfolio and our regulatory and manufacturing expertise. GW’s research explores the potential therapeutic application of cannabinoids and we have evaluated the pharmacology of a number of cannabinoids across a wide range of disease areas.

Our primary focus is on disorders of the central nervous system (CNS), including epilepsy. Our lead cannabinoid product is a liquid formulation of highly purified plant-derived cannabidiol, or CBD, (Epidiolex® in the United States). In June 2018, the FDA approved Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome, two rare and particularly difficult to treat forms of epilepsy. The product was launched in November 2018 and is now available by prescriptions in the U.S.

We commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States. GW is in the process of working with the FDA to identify the optimal path to NDA submission for Sativex in the U.S.

We have a deep pipeline of additional cannabinoid product candidates which include compounds in development for epilepsy, autism spectrum disorders, glioma and schizophrenia.

GW is in a unique position to develop and manufacture plant-derived cannabinoid formulations worldwide at sufficient quality, uniformity and scale for the purposes of pharmaceutical development and to meet international regulatory requirements.

PRODUCTS

Cannabidiol (CBD) Oral Solution

Now approved as Epidiolex in the United States; an investigational drug not approved for use by any other national regulatory agency.

US Residents, click here

Sativex® (nabiximols)

Sativex is a cannabinoid medicine for the treatment of multiple sclerosis spasticity.

Learn more

RECENT PIPELINE NEWS

Sep 04, 2019
CARLSBAD, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced
Aug 06, 2019
- Epidiolex U.S. Q2 net sales of $68.4 million - - Positive CHMP opinion clears way for an expected European approval in October - - Conference call today at 4:30 p.m. EST - CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the
Jul 26, 2019
If approved cannabidiol oral solution will be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsy GW’s cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the “high” associated with